Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1I7UO)

Drug Name

Cyclocreatine Drug Info

Synonyms

Cyclocreatinine; AM-285

Indication

Disease Entry	ICD 11	Status	REF
Virus infection	1A24-1D9Z	Discontinued in Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein kinase (PK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[3]
LY2801653	DM0KJDY	Biliary tract cancer	2C17	Phase 2	[3]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
ENMD-2076	DMJZVPB	Acute myeloid leukaemia	2A60	Phase 2	[3]
RV-568	DM652CM	Asthma	CA23	Phase 2	[4]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[5]
LX-7101	DM2LYIN	Glaucoma/ocular hypertension	9C61	Phase 1/2	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5491).
2	Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.